Quinazoline based EGFR inhibitors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 8, 2013
Grant Date -
Dec 1, 2011
app pub date -
Jun 8, 2011
filing date -
Sep 11, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully